Sun Pharmaceutical Industries Limited announced a final dividend of ₹5 per equity share for the financial year ended 31 March 2026, as recommended by its Board of Directors at a meeting held on 22 May 2026. The announcement accompanied the release of audited financial results for Q4 and the full fiscal year FY26. The stock closed at ₹1,852.40 on the NSE on the day of the announcement, down 2.06% or ₹38.90 during the session.

Dividend Details and FY26 Total Payout

The ₹5 final dividend, subject to shareholder approval, brings the total dividend payout for FY26 to ₹16 per share, combining the interim dividend of ₹11 per share declared on 31 January 2026 and the current final dividend. At the closing price of ₹1,852.40, the final dividend alone translates to a dividend yield of 0.27%, while the full-year payout of ₹16 per share implies a total FY26 yield of approximately 0.86%.

Comparison With Previous Year

In FY25, Sun Pharma had distributed a total of ₹16 per share as well, comprising an interim dividend of ₹10.50 per share in January 2025 and a final dividend of ₹5.50 per share in May 2025. The FY26 total payout is therefore flat year-on-year in absolute terms. However, the composition has shifted, with the interim component rising from ₹10.50 to ₹11 while the final dividend has decreased from ₹5.50 to ₹5. In FY24, the combined payout was ₹13.50 per share (interim ₹8.50 plus final ₹5), making FY26 a meaningful step up from two years ago.

Historical Dividend Trend

Sun Pharma's dividend track record over the past five years reflects a consistent upward trajectory in shareholder returns:

The absence of an interim dividend in FY22 and the sharp increase from FY22 to FY24 highlights the acceleration in payouts coinciding with the company's improving profitability cycle. The FY26 payout maintains the FY25 level, signalling a stable but not growing distribution for the year.

Valuation and Market Context

Sun Pharma currently trades at a price-to-earnings ratio of 41.25, a meaningful premium to the sector PE of 37.11 on the NIFTY PHARMA index, reflecting the market's premium pricing for the company's scale, specialty portfolio, and consistent earnings delivery. The stock is part of major indices including NIFTY 50, NIFTY PHARMA, and NIFTY HEALTHCARE INDEX, among 27 indices in total.

Within the 52-week range, the stock touched a high of ₹1,916.60 on 19 May 2026 and a low of ₹1,548 on 26 September 2025, placing the current price of ₹1,852.40 at approximately 83% of the 52-week range, near the upper band. The company's total market capitalisation stands at ₹4,44,116.90 crore.

Delivery and Volume Data

On the announcement date, 26,40,122 shares changed hands on the NSE. A delivery percentage of 49.15% indicates that roughly half of the traded volume resulted in actual share transfers rather than intraday squaring off, suggesting a meaningful proportion of conviction-based activity relative to speculative trading. Daily volatility is recorded at 1.33%, in line with the stock's typical movement profile for a large-cap pharma name.

The record date and payment timeline for the final dividend are yet to be announced and will be subject to shareholder approval at the upcoming Annual General Meeting.